For Investors

Therapeutic Vision, Inc. is a small research-driven pharmaceutical company focused on creating value through the development and commercialization of novel therapies for both veterinary and human markets. Our Business Model is to identify high-value intellectual property (IP), invest in the required research and development (R&D), and advance candidates to the stage of FDA Investigational New Animal Drug (INAD) or Investigational New Drug (IND) applications. We then monetize these assets through licensing the manufacturing and sales rights to earn royalties, or the outright sale of IP to strategic partners. Our proprietary compounds have demonstrated strong potential across veterinary and human indications.

Therapeutic Vision’s Pipeline Highlights include:

1) Kinostat^® (near-term launch) is a patented aldose reductase inhibitor eye drop formulation. For the Veterinary Market, the drug has received provisional FDA approval under the FDA MUMS designation for canine use pending completion of Chemical Manufacture and Control (CMC) procedures. It has been documented to prevent cataracts for up to 10 years from the onset of diabetes. With immediate funding, Kinostat will launch in 2026 to prevent cataracts in diabetic dogs. Once on the market, we will transition this drug to the Human Market by reformulating the eye drop for humans so that it can enter the $4.3B global human diabetic market by 2028. Indications for human use include diabetic keratopathy which is associated dry eye and normalization of corneal wound healing and ulcer repair. Our drug will provide safer outcomes for diabetics to undergo LASIK surgery. The Global Market Outlook for the treatment of diabetic keratopathy is projected to reach $16.92B by 2033.

2) Our topical Antioxidant Nutraceutical is a patented topical blend of natural antioxidants that include Astaxanthin, Resveratrol, Ethyl Pyruvate, and EGCG (green tea extract) that neutralizes harmful free radicals, reduces inflammation, preserves tear flow, and protects the eye from damage caused by aging, pollution, and chronic conditions such as dry eye. Its Current Status for the veterinary market, is that it is licensed to Aventix Animal Health as an FDA-sanctioned OTC veterinary device that is currently generating royalty revenue. Pending funding, a Human Market entry is planned as Therapeutic Eye Health to target the $3.4B global dry eye disease market with expected launch by 2027.

3) Multifunctional Redox Modulators (MFRMs™, also called Metal-Free Radical Modulators) are a new class of patented breakthrough class of orally active small molecules designed to preserve vision, hearing, and cognition. Unlike traditional antioxidants or metal chelators, which have failed to demonstrate neuroprotection in clinical trials, MFRMs combine dual mechanisms of action in a single molecule with potent radical scavenging activity that neutralizes damaging oxidative stress and selective transition metal binding activity that restores iron, copper, and zinc imbalance that is  implicated in neurodegeneration. Key Differentiators between MFRMs and current antioxidants / chelators include: 1) their unique molecular structure that enables both independent antioxidant and metal-binding activity; 2) their oral bioavailability with targeted tissue penetration into all parts of the eye, inner ear, and brain; 3) their stability advantage that prevents their autoxidation, a key limitation of the effectiveness of many antioxidants; and their low toxicity. MFRMs have demonstrated preclinical efficacy across multiple neurodegenerative models that include 1) Vision protection through prevention of retinal photoreceptor degeneration and retinal function preservation as well as delays in cataract formation caused by gamma irradiation, UV light, and ER stress, and corneal antioxidant protection and dry eye; 2} Hearing protection through prevention of cochlear hair cell loss and preservation of neural function in noise- and blast-induced hearing loss; and 3) Neurology protection against amyloid beta accumulation in brain, retina, and lens. Studies also show that MFRMs can remove zinc from neurotoxic amyloid beta–zinc complexes to enable subsequent amyloid beta degradation.

MFRMs have broad applications in targeting Healthy Aging, programs aimed at prolonging life free of chronic diseases that result in hearing  and vision loss as well as neurodegenerative diseases that include Alzheimer’s, Parkinson’s, ALS, Huntington’s and Usher syndrome. MFRMs have similar uses in the veterinary market where they represent the first of a kind drugs for targeting healthy aging in the companion pet markets. Importantly, MFRMs by targeting ferroptosis, a regulated form of cell death characterized by iron-dependent lipid peroxidation, have military applications for protection against the effects of traumatic brain injury (TBI) including protection of vision, auditory and cognitive changes  associated with TBI. The global market outlook for neuroprotective drugs was $68.6B in 2024, with growth projected to reach $127.1B by 2034 (7.0% CAGR). MFRMs uniquely address the unmet need for orally active, multi-mechanism neuroprotective agents across this expanding market.

Our research not only enhances understanding of ocular health but also contributes to the broader scientific community’s knowledge of drug-induced toxicology and neuroprotection. By collaborating with other researchers, institutions, and industry leaders, we are helping to pave the way for safer and more effective treatments for vision impairments. Additionally, our work in diabetic complications of the eye, neurodegenerative eye diseases, and oxidative stress-related conditions offer further insights into the interconnected pathways between metabolic diseases and vision loss. These discoveries will lead to new drug therapies that target both primary and secondary causes of blindness, hearing loss and cognitive loss.

Why Invest in Therapeutic Vision?  Looking toward the future, we continue to innovate and refine our pharmaceutical developments and we remain focused on expanding our research initiatives. The company will have near-term revenue with Kinostat’s launch in the veterinary market. This will be followed by a clear pathway to major human markets in neuroprotection with billion-dollar potential. We have a dual-market strategy that maximizes return on R&D investments and a proven regulatory progress and established licensing partnerships.